Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$36.95 USD

36.95
1,964,098

+0.37 (1.01%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $36.96 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

5 Reasons Why You Should Add Becton, Dickinson (BDX) Now

by Zacks Equity Research

Becton, Dickinson's (BDX) strategic acquisition of C.R. Bard provides it a strong foothold and exposure in MedTech. Here we take a look at five other factors that are likely to boost the stock.

    Zacks Equity Research

    BD (BDX) Launches PAXgene in Europe for Advanced DNA Testing

    by Zacks Equity Research

    Becton, Dickinson and Company's (BDX) PAXgene ccfDNA gets a commercial launch in Europe and enables improved DNA testing in comparison to standard EDTA tubes.

      Zacks Equity Research

      QIAGEN's QFT-Plus Approval in Japan to Expand Customer Base

      by Zacks Equity Research

      QIAGEN (QGEN) continues to strengthen Molecular Diagnostics business with focus on expanding QuantiFERON-TB Gold Plus customer base.

        Zacks Equity Research

        QIAGEN Strong on Molecular Diagnostics, Competition Rife

        by Zacks Equity Research

        QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and declining HPV sales.

          Zacks Equity Research

          QIAGEN (QGEN) Beats on Q4 Earnings and Revenues, Issues View

          by Zacks Equity Research

          QIAGEN's (QGEN) year-over-year growth in Q4 revenues is encouraging. Expansion in operating margin buoys optimism.

            Zacks Equity Research

            FDA Nod for QIAGEN's JAK2 Test Boosts Molecular Diagnostic

            by Zacks Equity Research

            QIAGEN (QGEN) strives to enhance Molecular Diagnostic segment, which was the highest revenue grosser in the last reported quarter.

              Zacks Equity Research

              QIAGEN Partners DiaSorin, Boosts Molecular Diagnostics Arm

              by Zacks Equity Research

              QIAGEN (QGEN) continues to adopt initiatives to strengthen Molecular Diagnostics business.

                Zacks Equity Research

                Abbott Boosts Diagnostics Arm With Alinity H-Series Launch

                by Zacks Equity Research

                Abbott (ABT) adopts initiatives to strengthen hold in the high-potential diagnostics market.

                  Zacks Equity Research

                  QIAGEN (QGEN) Faces Declining HPV Sales, Intense Competition

                  by Zacks Equity Research

                  QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and forex woes.

                    Zacks Equity Research

                    QIAGEN (QGEN) Meets Q3 Earnings, Lags Revenues, Keeps View

                    by Zacks Equity Research

                    QIAGEN's (QGEN) top line gains from strength in the Molecular Diagnostics space in Q3.